Dysphagia Days as an Assessment of Clinical Treatment Outcome in Eosinophilic Esophagitis

INTRODUCTION: The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study. METHODS: Dysphagia Days, defined as a yes answer to the following question: During any meal today, did food go down slowly or get stuck in your throat or chest? was assessed for cendakimab vs placebo. RESULTS: A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079). DISCUSSION: Dysphagia Days represents a relevant clinical end point to capture dysphagia-related symptoms.

Automated summary

The aim of this study was to evaluate Dysphagia Days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study. Dysphagia Days, defined as a yes answer to the question about food going down slowly or getting stuck in the throat or chest during any meal today, was assessed for cendakimab vs placebo. The results showed a significant reduction in the mean number of Dysphagia Days experienced with cendakimab, especially in steroid-refractory patients.